Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral AS01B/Ipilimumab + IV Nivolumab +/- Autologous Myeloid Dendritic Cells in Advanced Solid Tumors
NCT03707808Phase 2Active, not recruiting
- Sponsor
- UZ Brussel
- Start
- Jan 2018
- Primary completion
- Apr 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of autologous CD1c (BDCA-1)+ myDC in solid tumor, sponsored by UZ Brussel. Started Jan 2018; status: active, not recruiting.
02
Drugs
autologous CD1c (BDCA-1)+ myDC
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03707808.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03707808.